Table 2

Sensitivity, specificity, PPV and NPV (95% CIs in parentheses) of 2010 ACR/EULAR and 1987 ACR classification criteria in patients with very early inflammatory arthritis.

2010 ACR/EULAR classification criteria2010 ACR/EULAR classification criteria*1987 ACR classification criteria
DMARD startDiagnosis: RADiagnosis: RA and/or DMARD Start†DMARD startDiagnosis: RADiagnosis: RA and/or DMARD Start†,‡DMARD startDiagnosis: RADiagnosis: RA and/or DMARD Start†
Sensitivity0.80 (0.73–0.86)0.85 (0.78–0.90)0.79 (0.73–0.85)0.80 (0.74–0.86)0.85 (0.78–0.90)0.80 (0.73–0.85)0.55 (0,47–0.63)0.65 (0.56–0.73)0.57 (0.50–0.64)
Specificity0.63 (0.55–0.71)0.64 (0.56–0.71)0.66 (0.58–0.74)0.61 (0.53–0.70)0.64 (0.55–0.73)0.64 (0.56–0.73)0.76 (0.67–0.83)0.80 (0.72–0.86)0.80 (0.72–0.87)
PPV0.71 (0.65–0.78)0.68 (0.62–0.77)0.75 (0.69–0.82)0.82 (0.76–0,87)0.74 (0.64–0.78)0.78 (0.69–0.82)0.71 (0.62–0.79)0.73 (0.64–0.80)0.78 (0.70–0,85)
NPV0.73 (0.66–0.81)0.82 (0.76–0.87)0.70 (0.63–0.76)0.71 (0.66–0.81)0.78 (0.72–0.87)0.68 (0.63–0.76)0.60 (0.52–0.68)0.73 (0.65–0.80)0.59 (0.53–0.66)
  • *35 patients excluded because of ‘other better explanations’, that is, diagnosis of specific non-RA-disease within 3 months.

  • †this category comprises all RA patients (including 10 patients who declined DMARD and/or had contra-indications) and 27 DMARD treated patients with other diagnoses or UA

  • ‡(n = 17 after exclusion of ‘other better explanations’).

  • ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism; NPV, negative predictive value; PPV, positive predictive value; RA, rheumatoid arthritis.